Multiple sclerosis review.
作者信息
Goldenberg Marvin M
出版信息
P T. 2012 Mar;37(3):175-84.
Abstract
摘要
相似文献
1
Multiple sclerosis review.多发性硬化症综述
P T. 2012 Mar;37(3):175-84.
2
Efficacy and safety of siponimod for multiple sclerosis: Protocol for a systematic review and meta-analysis.西尼莫德治疗多发性硬化症的疗效和安全性：系统评价与荟萃分析方案
Medicine (Baltimore). 2019 Aug;98(34):e15415. doi: 10.1097/MD.0000000000015415.
3
[Effects of nutritional status on the multiple sclerosis disease: systematic review].[营养状况对多发性硬化症的影响：系统评价]
Nutr Hosp. 2018 Jan 19;35(1):211-223. doi: 10.20960/nh.1229.
4
Characteristics and correlates of coping with multiple sclerosis: a systematic review.应对多发性硬化症的特征及相关因素：一项系统综述
Disabil Rehabil. 2019 Feb;41(3):250-264. doi: 10.1080/09638288.2017.1387295. Epub 2017 Oct 10.
5
Cerebellar and/or Brainstem Lesions Indicate Poor Prognosis in Multiple Sclerosis: A Systematic Review.小脑和/或脑干病变提示多发性硬化预后不良：一项系统评价
Front Neurol. 2022 Apr 29;13:874388. doi: 10.3389/fneur.2022.874388. eCollection 2022.
6
Experiences of multiple sclerosis patients with self-management of fatigue: a qualitative systematic review protocol.多发性硬化症患者疲劳自我管理体验的定性系统评价方案
JBI Evid Synth. 2020 Mar;18(3):619-625. doi: 10.11124/JBISRIR-2017-003986.
7
Psychosocial adjustment in children and adolescents with a parent with multiple sclerosis: a systematic review.儿童和青少年中患有多发性硬化症的父母的心理社会适应：系统评价。
Clin Rehabil. 2010 Sep;24(9):789-801. doi: 10.1177/0269215510367982. Epub 2010 Aug 4.
8
[Radiologically isolated syndrome as a possible preclinical stage of primary-progressive multiple sclerosis].[放射学孤立综合征作为原发进展型多发性硬化症可能的临床前期阶段]
Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(8. Vyp. 2):35-39. doi: 10.17116/jnevro201811808235.
9
Paediatric Multiple Sclerosis: A Scoping Review of Patients' and Parents' Perspectives.儿童多发性硬化症：对患者及家长观点的范围综述
Children (Basel). 2021 Dec 25;9(1):11. doi: 10.3390/children9010011.
10
A systematic review of oral health in people with multiple sclerosis.多发性硬化症患者口腔健康的系统评价。
Community Dent Oral Epidemiol. 2020 Apr;48(2):89-100. doi: 10.1111/cdoe.12512. Epub 2019 Dec 9.
引用本文的文献
1
Role of isoflavones in multiple sclerosis.异黄酮在多发性硬化症中的作用。
IBRO Neurosci Rep. 2025 Aug 15;19:456-470. doi: 10.1016/j.ibneur.2025.08.012. eCollection 2025 Dec.
2
PD-1 Bispecific Killer Engager (PD-1 BiKE) effectively depletes effector T lymphocytes in experimental autoimmune encephalomyelitis.程序性死亡蛋白1双特异性杀伤衔接分子（PD-1双特异性衔接分子，PD-1 BiKE）可有效耗竭实验性自身免疫性脑脊髓炎中的效应性T淋巴细胞。
Front Immunol. 2025 Aug 13;16:1644903. doi: 10.3389/fimmu.2025.1644903. eCollection 2025.
3
Assessing the level of awareness and knowledge regarding multiple sclerosis among the Saudi community of the Al-Ahsa region.评估沙特阿赫萨地区社区对多发性硬化症的认知水平和知识掌握情况。
J Family Med Prim Care. 2025 Jun;14(6):2273-2279. doi: 10.4103/jfmpc.jfmpc_1838_24. Epub 2025 Jun 30.
4
The role of autophagy in the pathogenesis and treatment of multiple sclerosis.自噬在多发性硬化症发病机制及治疗中的作用
Autophagy Rep. 2025 Jul 22;4(1):2529196. doi: 10.1080/27694127.2025.2529196. eCollection 2025.
5
Fatigue and its correlation with anxiety and depression in patients with multiple sclerosis in China.中国多发性硬化症患者的疲劳及其与焦虑和抑郁的相关性。
Front Neurol. 2025 Jul 7;16:1604540. doi: 10.3389/fneur.2025.1604540. eCollection 2025.
6
Primary Progressive Multiple Sclerosis: New Therapeutic Approaches.原发性进行性多发性硬化症：新的治疗方法
Neuropsychopharmacol Rep. 2025 Sep;45(3):e70039. doi: 10.1002/npr2.70039.
7
High-Speed-Ventral-Plane Videography Identifies Specific Gait Pattern Changes in Cuprizone-Induced Demyelination in Mice.高速腹侧平面摄像术识别小鼠中铜离子螯合剂诱导脱髓鞘的特定步态模式变化。
Cells. 2025 Jun 24;14(13):969. doi: 10.3390/cells14130969.
8
MiR-124 and MiR-155 as Therapeutic Targets in Microglia-Mediated Inflammation in Multiple Sclerosis.微小RNA-124和微小RNA-155作为多发性硬化症中小胶质细胞介导炎症的治疗靶点
Cell Mol Neurobiol. 2025 Jul 7;45(1):63. doi: 10.1007/s10571-025-01578-6.
9
Experiences of People with Multiple Sclerosis in Sensor-Based Jump Assessment.多发性硬化症患者在基于传感器的跳跃评估中的体验。
Bioengineering (Basel). 2025 Jun 3;12(6):610. doi: 10.3390/bioengineering12060610.
10
Multiple sclerosis: etiology in the context of neurovascular unit and immune system involvement and advancements with blood-brain barrier models.多发性硬化症：神经血管单元和免疫系统参与背景下的病因学以及血脑屏障模型的进展
Front Immunol. 2025 Jun 10;16:1595276. doi: 10.3389/fimmu.2025.1595276. eCollection 2025.
本文引用的文献
1
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.奥瑞珠单抗治疗复发缓解型多发性硬化症：一项 2 期、随机、安慰剂对照、多中心试验。
Lancet. 2011 Nov 19;378(9805):1779-87. doi: 10.1016/S0140-6736(11)61649-8. Epub 2011 Oct 31.
2
Randomized trial of oral teriflunomide for relapsing multiple sclerosis.随机试验口服特立氟胺治疗复发型多发性硬化症。
N Engl J Med. 2011 Oct 6;365(14):1293-303. doi: 10.1056/NEJMoa1014656.
3
Treatment of walking impairment in multiple sclerosis with dalfampridine.用盐酸达非那新治疗多发性硬化症的步行障碍。
Ther Adv Neurol Disord. 2011 Mar;4(2):99-109. doi: 10.1177/1756285611403960.
4
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.在复发缓解型多发性硬化症中比较芬戈莫德与干扰素 β-1a：TRANSFORMS 研究的随机扩展。
Lancet Neurol. 2011 Jun;10(6):520-9. doi: 10.1016/S1474-4422(11)70099-0. Epub 2011 May 13.
5
Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab.多发性硬化症新型治疗策略的免疫机制-重点关注阿仑单抗。
Clin Immunol. 2012 Jan;142(1):25-30. doi: 10.1016/j.clim.2011.04.006. Epub 2011 Apr 15.
6
7
Insight into the mechanism of laquinimod action.洞察拉喹莫德作用机制。
J Neurol Sci. 2011 Jul 15;306(1-2):173-9. doi: 10.1016/j.jns.2011.02.019. Epub 2011 Mar 22.
8
Long-term daclizumab therapy in relapsing-remitting multiple sclerosis.在复发缓解型多发性硬化症中的长期达利珠单抗治疗。
Ther Adv Neurol Disord. 2009 Sep;2(5):291-7. doi: 10.1177/1756285609337992.
9
Pathophysiology of multiple sclerosis and the place of teriflunomide.多发性硬化症的病理生理学和特立氟胺的地位。
Acta Neurol Scand. 2011 Aug;124(2):75-84. doi: 10.1111/j.1600-0404.2010.01444.x. Epub 2010 Sep 29.
10
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.利妥昔单抗附加治疗突破性复发多发性硬化症：一项为期 52 周的 II 期试验。
Neurology. 2010 Jun 8;74(23):1860-7. doi: 10.1212/WNL.0b013e3181e24373.
Zotero 插件